Sepsis - Pipeline Insight, 2021

This “Sepsis - Pipeline Insight, 2021,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Sepsis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Sepsis Understanding

Sepsis: Overview

Sepsis is a life-threatning organ dysfunction caused by dysregulated host response to infection. Sepsis is sometimes called septicaemia or blood poisoning. If not recognized early, it can lead to septic shock, multiple organ failure and death. It is most frequently a serious complication of infection, particularly in low- and middle-income countries where it represents a major cause of maternal and neonatal morbidity and mortality. Sepsis develops when the immune system releases the chemicals in the bloodstream to fight an infection cause inflammation throughout the entire body instead. Sepsis is more common in People with chronic medical conditions, such as diabetes, lung disease, cancer, and kidney disease, People with weakened immune systems, babies under 1 year of age, elderly people especially if they have other health problems.

"Sepsis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines. The assessment part of the report embraces, in depth Sepsis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sepsis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Sepsis R&D. The therapies under development are focused on novel approaches to treat/improve Sepsis.

Sepsis Emerging Drugs Chapters

This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sepsis Emerging Drugs

Thymosin alpha 1: SciClone Pharmaceuticals

Thymosin alpha 1, generically referred to as thymalfasin, is a synthetic 28-amino acid peptide with multiple biological activities primarily directed towards immune response enhancement. SciClone developed and launched Thymosin alpha 1, under the trade name Zadaxin, for the treatment of hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections. The drug is also being developed for the treatment of non-small cell lung cancer (NSCLC), hepatocellular carcinoma, AIDS, sepsis and malignant melanoma. The drug is in phase 3 of development stage for the treatment of sepsis.

VBI-S: Vivacelle Bio

VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension. VBI-S is likely to be effective in septic shock due to COVID or bacteria even when current therapy has failed. VBI-S is an intravenously injectable fluid comprised of phospholipid nanoparticles that were specifically designed to shift the biophysical properties of the body's fluid volume in hypovolemic shock, due to sepsis, from non-survival to survival. The therapy is currently under phase II clinical evaluation for the treatment of hypovolemia due to sepsis/septic shock.

Sepsis: Therapeutic Assessment

This segment of the report provides insights about the different Sepsis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Sepsis

There are approx. 35+ key companies which are developing the therapies for Sepsis. The companies which have their Sepsis drug candidates in the most advanced stage, i.e. phase III include, SciClone Pharmaceuticals.

Phases

This report covers around 35+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Sepsis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Subcutaneous
• Intravenous
• Intramuscular
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Recombinant proteins
• Small molecule
• Cell therapy
• Liposome
• Vaccines
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sepsis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sepsis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs.

Sepsis Report Insights

• Sepsis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Sepsis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Sepsis drugs?
• How many Sepsis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sepsis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sepsis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Sepsis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• SciClone Pharmaceuticals
• Vivacelle Bio
• InflaRx
• Grifols
• Cidara Therapeutics
• AM-Pharma
• Asahi Kasei Pharma
• Sanofi
• Shionogi
• Paion
• Inoterm
• InflaRx GmbH
• Enlivex Therapeutics
• Biomedizinische Forschungsgesellschaft
• Abionyx
• Adrenomed
• TiGenix
• Tianjin Chasesun Pharmaceutical
• Suzhou Yabao Pharmaceutical
• Shaperon
• Genentech
• Noxopharm
• Vascular Biosciences
• Karyopharm Therapeutics
• Arch Biopartners
• Tetra Bio-Pharma
• Cellics Therapeutics
• Scioto Biosciences
• Agile Biotics

Key Products

• Thymosin alpha 1
• VBI-S
• Vilobelimab
• Albutein
• Rezafungin
• Recombinant human alkaline phosphatase
• ART-123
• Alirocumab
• Cefiderocol
• Remimazolam
• Nangibotide
• CaCP29
• Allocetra-OTS
• rTSST-1v
• CER-001
• Adrecizumab
• Cx 611
• Kukoamine B
• SY-005
• HY209
• DSTA 4637S
• NOX66
• NuSepin
• CAR Adjuvant
• Selinexor
• Metablok
• ARDS-003
• Lipocurc
• CTI-111
• SB-121
• ABX-605